Tag
A drug that modulates copper transport shows promise in restoring memory and clearing toxic Alzheimer's-associated proteins in preclinical models.
This case report documents transient multidomain functional improvements in an advanced Alzheimer's patient following high-dose psilocybin administration, with recovery of speech, continence, and social interaction over days to weeks.
This paper demonstrates that supervised fine-tuning with synthetic rationale data consistently harms prediction performance for Alzheimer's disease detection compared to label-only fine-tuning, across many configurations and model families. The degradation persists despite high-quality rationales and is attributed to a conflict between narrative plausibility and discriminative optimization.
This paper proposes a medication-aware framework that integrates medication adherence data with transaction monitoring to detect cognitively risky financial events for Alzheimer's patients, showing improved recall during medication-induced vulnerability windows.
A 2025 review and pilot trial show that creatine supplementation raises brain energy levels and slows cognitive decline in early Alzheimer's patients by 30%, highlighting the supplement's overlooked neurological benefits.
A new preclinical study suggests that loss of estrogen production in the brain after menopause may disrupt the extracellular matrix in the hippocampus, offering a potential explanation for why women face higher Alzheimer's risk.
This paper presents MEMOR-E, a mobile quadruped robot with a tablet interface that uses fine-tuned and in-context learning with LLMs to provide personalized, stage-aware cognitive assistance for Alzheimer's patients, including medication reminders and memory interactions, with explainable AI for caregiver oversight.